Adverse Event Information Sample Clauses

Adverse Event Information. WCCI shall provide notice to Paratek of any Adverse. Events that occur during the Term, including without limitation, all filings made with Regulatory Authorities with respect to Adverse Events promptly after making such filings. WCCI shall make available to Paratek for review and copy at Paratek’s expense, upon reasonable request, all Adverse Event information and product complaint information relating to Lead Candidates and Products as compiled, prepared and filed by WCCI with the FDA or similar Regulatory Authorities in the normal course of business in connection with the Development, Commercialization or sale of any Lead Candidates or Products. Paratek acknowledges and agrees that such information shall be the Confidential Information of WCCI and subject to the provisions of Article 6 hereof.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Adverse Event Information. Within six months after the commencement of the Development Phase, MMD will establish a protocol for the timely handling and transmission of adverse event information. MMD and TKT shall promptly notify each other of any adverse event information relating to * in accordance with such protocol.
Sample 1Sample 2See All (4)
Adverse Event Information. Aegis will provide Opiant with copies of all reports of any adverse event which Aegis must report to a Regulatory Authority under applicable Law or which is serious, such as any adverse event involving Materials that results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in disability, congenital anomaly or is medically important (i.e., may require other medical or surgical intervention to prevent other serious criteria from occurring), and which Aegis has reason to believe is associated with any or all Materials as soon as reasonably practicable, but in no event more than forty-eight (48) hours following receipt of notice thereof by Aegis, including without limitation from Aegis’ Contract Manufacturer or customers. Each Party shall promptly advise the other Party of any complaints, adverse reaction reports, safety issues or toxicity issues relating to any Material of which it becomes aware. If either Party determines that any Material causes an adverse event, such Party shall notify the other Party as soon as reasonably practicable, but in no event more than forty-eight (48) hours following such determination.
Sample 1
Adverse Event Information. In addition to the updates described in Section 2.3.1, AMBION shall provide ROSETTA with copies of all adverse and product complaint information relating to Collaboration Products and/or Collaboration Services as such information is compiled or prepared by AMBION in the normal course of business in connection with the Development or Commercialization of any Collaboration Product and/or Collaboration, Service and, in any event, within time frames consistent with reporting obligations under Applicable Laws.
Sample 1

Related to Adverse Event Information

  • Event Information Number: 230202 Addendum 1 Title: Security Systems Products and Services Type: Request for Proposal Issue Date: 2/2/2023 Deadline: 3/17/2023 03:00 PM (CT) Notes: This is a solicitation issued by The Interlocal Purchasing System (TIPS), a department of Texas Region 8 Education Service Center. It is an Indefinite Delivery, Indefinite Quantity ("IDIQ") solicitation. It will result in contracts that provide, through adoption/"piggyback" an indefinite quantity of supplies/services, during a fixed period of time, to TIPS public entity and qualifying non-profit "TIPS Members" throughout the nation. Thus, there is no specific project or scope of work to review. Rather this solicitation is issued as a prospective award for utilization when any TIPS Member needs the goods or services offered during the life of the agreement. IF YOU CURRENTLY HOLDS TIPS CONTRACT 200203 SECURITY SYSTEMS PRODUCTS AND SERVICES ("200203"). YOU MUST RESPOND TO THIS SOLICITATION TO PREVENT LAPSE OF CONTRACT UNLESS YOU HOLD ANOTHER CURRENT TIPS CONTRACT THAT COVERS ALL OF YOUR SECURITY OFFERINGS. THIS AWARDED CONTRACT WILL REPLACE YOUR EXPIRING TIPS CONTRACT 200203. Address: Region 8 Education Service Center 0000 XX Xxxxxxx 000 Xxxxx Pittsburg, TX 75686 Phone: +0 (000) 000-0000 Email: xxxx@xxxx-xxx.xxx Contact: Xxxxxx Xxxxxxx Address: 000 - 00000 Xxxxx Xxx. Abbotsford, BC V2T6H1 Canada Phone: (000) 000-0000 Fax: (000) 000-0000 Toll Free: (000) 000-0000 Email: xxxxxxxxx@xxxxxxxxxx-xxxxxxx.xxx Web Address: xxx.xxxxxxxxxx-xxxxxxx.xxx By submitting your response, you certify that you are authorized to represent and bind your company. Pricing Form 1 must be downloaded from the “Attachments” section of the IonWave eBid System, reviewed, properly completed as instructed, and uploaded to this location. Pricing Form 2 must be downloaded from the “Attachments” section of the IonWave eBid System, reviewed, properly completed as instructed, and uploaded to this location.

  • Patient Information Each Party agrees to abide by all laws, rules, regulations, and orders of all applicable supranational, national, federal, state, provincial, and local governmental entities concerning the confidentiality or protection of patient identifiable information and/or patients’ protected health information, as defined by any other applicable legislation in the course of their performance under this Agreement.

  • Adverse Events Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.

  • Client Information Protected Health Information in any form including without limitation, Electronic Protected Health Information or Unsecured Protected Health Information (herein “PHI”);

  • Adverse Event Reporting Both Parties acknowledge the obligation to comply with the Protocol and / or applicable regulations governing the collection and reporting of adverse events of which they may become aware during the course of the Clinical Trial. Both Parties agree to fulfil and ensure that their Agents fulfil regulatory requirements with respect to the reporting of adverse events.

  • Alert Information As Alerts delivered via SMS, email and push notifications are not encrypted, we will never include your passcode or full account number. You acknowledge and agree that Alerts may not be encrypted and may include your name and some information about your accounts, and anyone with access to your Alerts will be able to view the contents of these messages.

  • Factsheet Information General information entered into the higher education institutions’ profile and updated by the higher education institution. The general information about the institution is accessible to students. Autumn term [day/month] 04/30 Spring term [day/month] 09/30 Autumn term [day/month] 06/30 Spring term [day/month] 11/30 xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/en Requirement Details Website Other Transcript xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/Erasmus--Europe/How-to-Apply/82 2 Other Copy of Passport xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/Erasmus--Europe/How-to-Apply/82 2 Other Learning Agreement xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/Erasmus--Europe/How-to-Apply/82 2 Available infrastructure ad- justed for people with: Description of infras- tructure Contact details Website for information Infrastructure Not present xxxxx://xxxxxxx.xxxxxx.xxx.xx /en The institution will guide incoming mobile participants in finding accommodation, according to the requirements of the Erasmus Charter for Higher Education. Information and assistance can be provided by the following contact points and information sources: Contact email Contact phone Websites for information xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/16/Accom modation/474 The institution will provide assistance, when required, in securing visas for incoming and outbound mobile partici- pants, according to the requirements of the Erasmus Charter for Higher Education. Information and assistance can be provided by the following contact points and information sources: Contact email Contact phone Websites for information xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/16/Visa-an d-Residence-Permit/472 The institution will provide assistance in obtaining insurance for incoming and outbound mobile participants, accord- ing to the requirements of the Erasmus Charter for Higher Education. The receiving institution will inform mobile par- ticipants of cases in which insurance cover is not automatically provided. Information and assistance can be provided by the following contact points and information sources: Contact email Contact phone Websites for information xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/16/Healt h-Insurance/473

  • Market Information Exchange and Xxxxxxxxxx brochures and research are often provided as trading tools. In addition, a CTS Platform may also contain certain market information. Customer acknowledges that: (a) any information Xxxxxxxxxx’x research department may communicate to Customer does not constitute an offer to sell or a solicitation of any offer to buy any Contract; (b) such recommendations and information, although based upon information obtained from sources believed by Xxxxxxxxxx to be reliable, are incidental to Xxxxxxxxxx’x business as a futures commission merchant, may be incomplete and not subject to verification, and will not serve as the primary basis for any decision by Customer; (c) Xxxxxxxxxx makes no representation, warranty, or guarantee as to, and shall not be responsible for, the accuracy or completeness of any information or trading recommendation furnished to Customer; (d) recommendations to Customer as to any particular transaction at any given time may differ among Xxxxxxxxxx’x personnel due to diversity in analysis of fundamental and technical factors and may vary from any standard recommendation made by Xxxxxxxxxx in its market letters or otherwise; and (e) Xxxxxxxxxx has no obligation or responsibility to update any market recommendations or information it communicates to Customer. Customer understands that Xxxxxxxxxx and its officers, directors, affiliates, stockholders, representatives, or associated persons may have positions in and may intend to buy or sell Contracts which are the subject of market recommendations furnished to Customer, and that the market positions of Xxxxxxxxxx or any such officer, director, affiliate, stockholder, representative, or associated person may or may not be consistent with the recommendations furnished to Customer by Xxxxxxxxxx.

  • OTHER PERTINENT INFORMATION Applicant owns the upland adjoining the lease premises.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!